Mycoplasma Diagnostics Market - Forecast(2024 - 2030)

Mycoplasma Diagnostics Market Overview

Mycoplasma Diagnostics Market Size is estimated to reach $1.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 9.8% over the forecast period of 2022-2027. Mycoplasma pneumonia, often known as M.pneumonia, is a bacteria that causes a respiratory illness that spreads quickly when it comes into contact with respiratory fluids. It's also known as walking pneumonia since the germs may quickly spread in public places. M. pneumonia bacteria produce hydrogen peroxide and superoxide, causing injury to epithelial cells and their associated cilia. Lung infections caused by M. pneumonia are sometimes referred to as “walking pneumonia” since symptoms are generally mild. Sometimes M. pneumonia can cause more serious lung infections that require care in a hospital. Mycoplasma pneumonia infections can be diagnosed in clinical laboratories using culture, serology, or nucleic acid amplification procedures, although most Mycoplasma pneumonia infections are self-limiting, doctors treat pneumonia caused by M. pneumonia with antibiotics. Antibiotics such as Macrolides, Fluoroquinolones, Tetracyclines, azithromycin, doxycycline, moxifloxacin are used by doctors to treat this pneumonia. As per CDC, 2 million cases of M. pneumonia infections occur each year in the United States. Factors such as biopharmaceutical firms' high R&D spending, increased government research programs, and financing, technical improvements, rising demand for rapid, accurate, and economical testing, and rising cell culture contamination are all boosting the market for mycoplasma diagnostics over the forecast period 2022 – 2027.

Report Coverage

The report: “Mycoplasma Diagnostics Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Mycoplasma Diagnostics Market.

By Products: Instruments, Kits & Reagents (Nucleic Acid Detection Kits, Stains, Elimination Kits, Standards & Controls) Services and Others.
By Technology: PCR, ELISA, Enzymatic methods, DNA Staining, and Others.
By Application: Cell line testing, Bio-production testing, and Others.
By End User: Hospitals, Diagnostic Laboratories, Clinics, and Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, North America held a dominant market share in the year 2021, owing to advanced health infrastructure in countries like the United States and Canada.
• The Mycoplasma Diagnostics Market is predicted to increase owing to the increasing number of cardiac cases hence hectic lifestyle, consumption of unhealthy food, and addiction.
• However, the high cost of equipment and setup along with strict government restrictions in some countries hampers market growth over the forecast period 2022-2027.
• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Mycoplasma Diagnostics Market Report.

Mycoplasma Diagnostics Market Segmentation Analysis- By Technology

Mycoplasma Diagnostics Market based on technology can be further segmented PCR, ELISA, Enzymatic methods, DNA Staining, and Others. PCR segment held a dominant market share in the year 2021, owing to the increased use in clinical diagnostics, rising demand for personalised and precision medicine, and technical advances and applications in drug development. A PCR test's sensitivity level can be as low as a single organism, allowing for the detection of mycoplasmas in both antibiotic-treated and asymptomatic patients. ATCC, the world's leading resource and standards organisation for biological materials, announced a new PCR-based service to identify mycoplasma contamination in cell cultures in July 2019, hence enhancing the segment growth.

However, the DNA staining segment is estimated to grow with the fastest CAGR rate of 10.6% over the forecast period 2022-2027. Owing to the variety of kits available for clinical laboratories to test mycoplasma samples to find out related results. The DNA staining method used a specific staining dye that binds with a particular DNA segment and gives a fluorescence effect to that particular DNA segment in blotting. Some examples of kits available on market are PlasmoTest, Mycoplasma Hoechst Stain Kit, EZdetectTM Hoechst stain kit, The MycoFluor™ Mycoplasma Detection Kit, and others. The increasing research and developments and launch of new products are expected to drive the segment over the forecast period 2022-2027.

Mycoplasma Diagnostics Market Segmentation Analysis- By End User

Mycoplasma Diagnostics Market based on end user can be further segmented into Hospitals, Diagnostic Laboratories, Clinics, and Others. The Hospital segment held a dominant market share in the year 2021. This is owing to the use of improved diagnostic technology overtime in hospitals. The majority of hospitals have their own clinical laboratories or tie-up. In such clinical laboratories, the diagnostic of mycoplasma is possible due to advanced technology like PCR assay, enzymatic methods for mycoplasma diagnostics, DNA staining, and other technique which drives the segment growth.

However, Diagnostic laboratories are estimated to grow with the fastest CAGR rate of 10.2% over the forecast period 2022-2027. Owing to the increasing number of diagnostic laboratories across the globe and reliable techniques used for diagnostic like blood tests using antibodies to M. pneumonia, direct detection techniques such as detection of samples collected from respiratory secretion, blood, fluid, tissue samples or by DNA diagnostic methods, are enhancing the segment growth in the forecast period.

Mycoplasma Diagnostics Market Segmentation Analysis- By Geography

The Mycoplasma Diagnostics Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 35% in 2021. Owing to the repeated occurrence of mycoplasma pneumonia every year, research states that around 2 million M. pneumonia cases are found annually. Pneumonia is one of the major reasons to hospitalize children in America, as per the American Thoracic Society. Such increasing cases of M. pneumonia and also improved diagnostic methods in North America.

Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. Mycoplasma infection spreads through respiratory fluid, and infection chances are high in populated areas. Asia-Pacific is home to more than 60% world population. Hence people are at high risk of mycoplasma infection. According to research conducted by ‘The Group of Korean Academy of Paediatric Allergy and Respiratory Diseases’ in 2020, the study of 65,243 children in the age group (0 -18 years) showed that more than 80% of children found macrolide sensitive mycoplasma infection. Increasing government initiative to break such infection, increase living standers, and improved healthcare infrastructure, hence enhancing the regional expansion.

Mycoplasma Diagnostics Market Drivers

Increasing Prevalence of Respiratory Diseases is Anticipated to Drive Market Growth

With the increase in respiratory tract infections around the world, there is an emerging need for mycoplasma diagnostic. India which ranks number two in population and with 18% of the global population reported 41,996,260 cases and 3,740 deaths from respiratory infection, as per the 2019 report published in the National Health Portal of India. The major market player with advanced technology for mycoplasma diagnostic kits, advancements in technology such as home delivery of such kits for self-testing mycoplasma infection is driving the market.

Advance Technology for Mycoplasma Testing Aid Market Growth

Diagnosis of Mycoplasma is very difficult without using advanced technology, as it shows atypical symptoms and the fastidious nature of the pathogen. To detect the disease advanced level techniques such as PCR, ELISA, and enzymatic methods are used. In clinical laboratories and diagnostic centers, PCR is used attributed to the high sensitivity of PCR mycoplasma identification is 96%, with 86% and 99% positive and negative predictive values, respectively with a 96% accuracy rate in diagnosing mycoplasma status.

Mycoplasma Diagnostics Market Challenges

Lack of Skilled Technicians is Hampering Market Growth

Chain of hospitals, clinical laboratories, and diagnostic centers spreads all over the globe. With the increasing global population, there is an increased load on the healthcare system to provide efficient service. Some factors slugging the growth of healthcare sectors such as high investment in infrastructure, equipment, and machinery. Along with it, the lack of skilled professionals is one of the major challenges. According to the WHO, the number of healthcare workers worldwide would decline to 12.9 million by 2035 from 59.3 million in 2019. The global shortage of healthcare personnel is linked to a number of factors, including an aging workforce, a decline in the number of persons joining the profession, early retirements, insufficient training, and increased demands from a growing and aging population, which hamper market growth over the forecast period 2022-2027.

Mycoplasma Diagnostics Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Mycoplasma Diagnostics Market. The top 10- Mycoplasma Diagnostics Market companies are-

1. Thermo Fisher Scientific Inc.
2. Merck KGaA,
3. Lonza
4. PromoCell GmbH
5. American Type Culture Collection
6. Charles River Laboratories International Inc.
7. Bionique Testing Laboratories Inc.
8. Abbott
9. Affymetrix
10. bioMerieux

Recent Developments

• In February 2022, Merck KGaA, build a new life-science unit that helps to consolidate the company CDMO and contract testing units with other operations. This unit is built with the inspiration from Life Science Services. The new life-science unit will be in Burlington, Massachusetts.
• In November 2020, Thermo-Fisher scientific and Innoforce, a bio-innovation enabling company signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, which is expected to be completed by the end of 2022.
• In April 2019, Lonza launched SimpliFH services which are integrated first-in-human service packages for poorly soluble small molecules. This product will enhance drug substance developments and accelerate the human pathway for candidate molecules. It also reduces cost, time, and complexity in the study of drugs.

Relevant Titles

Bacterial Conjunctivitis Treatment Market - Forecast(2022 - 2027)

Report Code: HCR 0251

Bacterial & Viral Specimen Collection Market - Forecast(2022 - 2027)

Report Code: HCR 1379

Ampicillin Market Analysis - Forecast(2022 - 2027)

Report Code: CMR 0246

For more Lifesciences and Healthcare Market reports, please click here